Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
- Conditions
- Ovarian Cancer
- Interventions
- Registration Number
- NCT00849667
- Lead Sponsor
- Morphotek
- Brief Summary
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 1100
- A histologically or cytologically confirmed diagnosis of non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies
- Must have measurable disease by CT or MRI scan
- Must have relapsed radiologically with a randomization date within ≥6 and < 24 months of completion of first-line platinum chemotherapy
- Have been treated with debulking surgery and first-line platinum and taxane based chemotherapy.
- Prior bevacizumbab maintenance is allowed. The last dose of bevacizumab must have been at least 30 days before study Day 1. No cytotoxic maintenance therapy (e.g. taxane) or cancer vaccine therapy is allowed.
- Must be a candidate for carboplatin and taxane therapy
- Neurologic function: neuropathy (sensory and motor) ≤CTCAE Grade 1
- Subjects who never responded to first-line platinum-based therapy or whose first relapse occurs <6 months or >24 months from the last platinum therapy
- Subjects who have received other therapy to treat their ovarian cancer since relapse
- Known central nervous system (CNS) tumor involvement
- Evidence of other active invasive malignancy requiring treatment in the past 5 years
- Known allergic reaction to a prior monoclonal antibody therapy or have any documented HAHA
- Previous treatment with MORAb-003 (farletuzumab)
- Clinical contraindications to use of a taxane
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Farletuzumab-matched placebo Participants will receive farletuzumab-matched placebo (0.9 percent \[%\] saline) administer as an IV infusion weekly, followed by taxane (paclitaxel \[175 mg/m\^2\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab-matched placebo (0.9% saline), administer as IV infusion, weekly is given until disease progression. Farletuzumab (1.25 mg/kg) Taxane Participants will receive farletuzumab 1.25 milligram per kilogram (mg/kg) administer as an intravenous (IV) infusion weekly, followed by taxane (paclitaxel \[175 milligram per meter square {mg/m\^2}\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain area under curve \[AUC\] 5-6 milligram per milliliter per minute \[mg/mL/minute\]), administer as IV infusion, every three weeks, on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 1.25 mg/kg, administer as IV infusion, weekly is given until disease progression. Placebo Taxane Participants will receive farletuzumab-matched placebo (0.9 percent \[%\] saline) administer as an IV infusion weekly, followed by taxane (paclitaxel \[175 mg/m\^2\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab-matched placebo (0.9% saline), administer as IV infusion, weekly is given until disease progression. Farletuzumab (2.5 mg/kg) Taxane Participants will receive farletuzumab 2.5 mg/kg administer as an IV infusion weekly, followed by taxane (paclitaxel \[175 mg/m\^2\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 2.5 mg/kg, administer as IV infusion, weekly is given until disease progression. Farletuzumab (1.25 mg/kg) Carboplatin Participants will receive farletuzumab 1.25 milligram per kilogram (mg/kg) administer as an intravenous (IV) infusion weekly, followed by taxane (paclitaxel \[175 milligram per meter square {mg/m\^2}\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain area under curve \[AUC\] 5-6 milligram per milliliter per minute \[mg/mL/minute\]), administer as IV infusion, every three weeks, on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 1.25 mg/kg, administer as IV infusion, weekly is given until disease progression. Farletuzumab (2.5 mg/kg) Carboplatin Participants will receive farletuzumab 2.5 mg/kg administer as an IV infusion weekly, followed by taxane (paclitaxel \[175 mg/m\^2\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 2.5 mg/kg, administer as IV infusion, weekly is given until disease progression. Placebo Carboplatin Participants will receive farletuzumab-matched placebo (0.9 percent \[%\] saline) administer as an IV infusion weekly, followed by taxane (paclitaxel \[175 mg/m\^2\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab-matched placebo (0.9% saline), administer as IV infusion, weekly is given until disease progression. Farletuzumab (2.5 mg/kg) Farletuzumab Participants will receive farletuzumab 2.5 mg/kg administer as an IV infusion weekly, followed by taxane (paclitaxel \[175 mg/m\^2\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 2.5 mg/kg, administer as IV infusion, weekly is given until disease progression. Farletuzumab (1.25 mg/kg) Farletuzumab Participants will receive farletuzumab 1.25 milligram per kilogram (mg/kg) administer as an intravenous (IV) infusion weekly, followed by taxane (paclitaxel \[175 milligram per meter square {mg/m\^2}\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain area under curve \[AUC\] 5-6 milligram per milliliter per minute \[mg/mL/minute\]), administer as IV infusion, every three weeks, on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 1.25 mg/kg, administer as IV infusion, weekly is given until disease progression.
- Primary Outcome Measures
Name Time Method Progression-free Survival (PFS) From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (up to 44 months) PFS was defined as the time (in months) from the date of randomization to the date of the first observation of progression based on the independent radiologic assessment (modified response evaluation criteria in solid tumors \[RECIST\]), or date of death, whatever the cause. As per RECIST, disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. If progression or death was not observed for a participant, the PFS time was censored at the date of the last tumor assessment without evidence of progression before the date of initiation of further antitumor treatment, or the cutoff date (whichever was earlier).
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Length of Second Remission Greater Than First Remission From the date of last dose of platinum-based chemotherapy to date of relapse and date of last dose of platinum-based chemotherapy to first observation of progression (up to 48 months) Length of first remission was defined as a.) the period of time (in months) from the date of completion of previous platinum-based chemotherapy until date of first relapse (that is, first observation of progression). It was assumed that the date of first relapse was the earlier of progression by CA-125 or progression by radiologic assessment, as judged by the investigator using GCIG criteria. b.) the period of time (in months) from the date of completion of previous platinum-based chemotherapy (used prior to study entry) until date of randomization. The length of the second remission was defined as the period of time (in months) from the date of completion of platinum-based chemotherapy until the first observation of progression based on GCIG criteria. Based on GCIG criteria, disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.
Duration of Tumor Response From the first date of confirmed objective response (CR or PR) to first date of progression or death due to any cause (up to 48 months) Duration of response was defined as the time (in months) from first documentation of objective response (confirmed CR or PR) to the first documentation of objective tumor progression or death due to any cause. Duration of response was derived only for those participants with objective evidence of confirmed CR or PR.
Overall Survival (OS) From the date of randomization until date of death from any cause, or study termination by sponsor, whichever came first (up to 48 months) OS was defined as the time (in months) from the date of randomization to the date of death, due to any cause. If death was not observed for a participant, the survival time was censored on the last date the participant was known to be alive or the cutoff date, whichever was earlier.
Cancer Antigen-125 (CA-125) Progression-Free Survival From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (up to 44 months) CA-125 PFS was defined as the time (in months) from the date of randomization until the date of the first observation of progression based on the Rustin criteria, or date of death, whatever the cause. If progression or death was not observed for a participant, the CA-125 PFS time was censored at the date of the last CA-125 assessment without evidence of progression before the date of initiation of further antitumor treatment or the "primary analysis cut off" date, whichever was earlier. Based on Rustin criteria, progressive disease (PD) was a rise in CA125 since beginning of consolidation or previously normal CA125 that rises to greater than or equal to (\>=) 2 multiple (\*) ULN with either event documented on two occasions or CA-125 \>=2\*nadir value with either event documented on two occasions.
Progression-Free Survival Based on Gynecologic Cancer InterGroup (GCIG) Criteria From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (up to 44 months) PFS using GCIG criteria was defined as time (in months) from date of randomization until date of first observation of progression based on GCIG criteria, or date of death, whatever the cause. If progression or death was not observed for a participant, GCIG PFS time was censored at later date of last tumor assessment or CA-125 assessment without evidence of progression before date of initiation of further antitumor treatment or the "primary analysis cut off" date, whichever was earlier. Disease progression per GCIG: Participants with elevated CA-125 pretreatment and normalisation of CA-125 must show evidence of CA-125 \>=two times ULN on two occasions at least one week apart or participants with elevated CA-125 pretreatment, which never normalises must show evidence of CA-125 \>=two times nadir value on two occasions at least one week apart or participants with CA-125 in normal range pretreatment must show evidence of CA-125 \>=two times ULN on two occasions at least one week apart.
Time to Tumor Response (TTR) From the date of randomization to first documentation of objective response (up to 48 months) Time to tumor response was defined as the time (in months) from the date of randomization to first documentation of objective tumor response. Time to tumor response was derived for those participants with objective evidence of CR or PR.
Percentage of Participants With Serologic Response (SR) Up to 48 months SR was defined as either normalization, 75% response, or 50% response using the Rustin criteria. Percentage of participants with 50% SR, 75% SR and SR leading to normalization were reported. A 50% response according to CA-125 was defined as a 50% decrease in serum CA-125 levels, as determined through a series of four CA-125 samples (one baseline sample with an elevated level, the sample that showed a 50% decrease, and a confirmatory sample at the decreased level). A 75% response was established if there had a serial decrease in serum CA-125 levels of 75% over three samples. In both the 50% and 75% response definitions, the final sample was analyzed at least 28 days after the previous sample.
Time to 50% Serologic Response (TSR) From the date of randomization to first documentation of 50% SR (up to 48 months) TSR was defined as the time (in months) from the date of randomization to first documentation of 50% SR. A 50% response according to CA-125 was defined as a 50% decrease in serum CA-125 levels, as determined through a series of three CA-125 samples (one baseline sample with an elevated level, the sample that showed a 50% decrease, and a confirmatory sample at the decreased level).
Vd: Volume of Distribution of Total Carboplatin and Total Paclitaxel Cycle 2 Week 1 Day 1: 0-45 hours post-dose (cycle length=21 days) Mean Functional Assessment of Cancer Therapy-Ovarian Treatment Outcome Index (FACT-O TOI) Scores Cycle 3, Cycle 6, Cycle 12 (each cycle length=21 days) Participant-reported Quality of Life (QoL) was measured using the Functional Assessment of Cancer Therapy-Ovarian (FACT-O), version 4 and reported in the Treatment Outcome Index (TOI) format. TOI is a 26-item subset of the FACT-O questionnaire composed of the raw sum of the physical well-being subscale (7 items), the functional well-being subscale (7 items), and the ovarian cancer subscale (12 items). Each item was scored on a scale of 0 (not at all) to 4 (very much). Some items were reversed scored. Scores from each subsection were summed into one composite score, termed the FACT-O TOI score which ranged from 0 to 104 and a higher score reflected better QoL. As per planned analysis, farletuzumab treatment groups 1.25 mg/kg and 2.5 mg/kg were pooled for the QoL assessment.
Percentage of Participants With Objective Response From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (up to 48 months) Objective response was defined as either a confirmed complete response (CR) or confirmed partial response (PR) as assessed by investigator based on response evaluation criteria in solid tumors version 1.1 (RECIST version 1.1). CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.
Duration of 50% Serologic Response From the first date of documentation of response to first documentation of serologic progression or death due to any cause (up to 48 months) Duration of SR was defined as the time (in months) from first documentation of response to the first documentation of 50% serologic progression or death due to any cause. For responding participants who did not have serologic progression or did not die and who 1) were either still on study at the time of an analysis, 2) were given antitumor treatment other than study treatment, or 3) were withdrawn from study follow-up before documentation of serologic progression, the duration of SR was censored at the last date the participant was known to be without serologic progression. A 50% response according to CA-125 was defined as a 50% decrease in serum CA-125 levels, as determined through a series of three CA-125 samples (one baseline sample with an elevated level, the sample that showed a 50% decrease, and a confirmatory sample at the decreased level).
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of Total Carboplatin and Total Paclitaxel Cycle 2 Week 1 Day 1: 0-45 hours post-dose (cycle length=21 days) AUC (0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of Total Carboplatin and Total Paclitaxel Cycle 2 Week 1 Day 1: 0-45 hours post-dose (cycle length=21 days) Percentage of Participants With Clinical Benefit Up to 48 months Clinical benefit was defined as a confirmed CR or a confirmed PR, or stable disease (SD) using RECIST 1.0 criteria. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non target lesions.
Cmax: Maximum Observed Plasma Concentration of Total Carboplatin and Total Paclitaxel Cycle 2 Week 1 Day 1: 0-45 hours post-dose (cycle length=21 days) T1/2: Terminal Half-life of Total Carboplatin and Total Paclitaxel Cycle 2 Week 1 Day 1: 0-45 hours post-dose (cycle length=21 days) CL: Clearance of Total Carboplatin and Total Paclitaxel Cycle 2 Week 1 Day 1: 0-45 hours post-dose (cycle length=21 days)
Trial Locations
- Locations (342)
Hematology Oncology P.C.
🇺🇸Stamford, Connecticut, United States
Loyola University Chicago
🇺🇸Maywood, Illinois, United States
Mercy Medical Center
🇺🇸Baltimore, Maryland, United States
Sparrow Regional Cancer Center
🇺🇸Lansing, Michigan, United States
John Hopkins University
🇺🇸Baltimore, Maryland, United States
Weinberg Cancer Institute at Franklin Square
🇺🇸Baltimore, Maryland, United States
Kettering Medical Center
🇺🇸Kettering, Ohio, United States
Baylor Sammons Cancer Center
🇺🇸Dallas, Texas, United States
The Moncton Hospital
🇨🇦Moncton, New Brunswick, Canada
Magee-Womens Hospital of UPMC
🇺🇸Pittsburgh, Pennsylvania, United States
University Hospitals of Cleveland
🇺🇸Cleveland, Ohio, United States
University of Texas Health Science Center at Houston Medical School
🇺🇸Houston, Texas, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Utah Cancer Specialists
🇺🇸Salt Lake City, Utah, United States
Morristown Memorial Hospital
🇺🇸Morristown, New Jersey, United States
CER Instituto Medico
🇦🇷Quilmes, Argentina
St. Joseph's Hospital, Barrow Neurology Clinics
🇺🇸Phoenix, Arizona, United States
Alexandra Hospital
🇬🇷Athens, Greece
Veszprém Megyei Önkormányzat Csolnoky Ferenc Kórház-Rendelöintézet
🇭🇺Veszprém, Hungary
Gynecologic Oncology Associates
🇺🇸Newport Beach, California, United States
General Oncology Hospital Kifissias "Oi Agioi Anargyroi"
🇬🇷Athens, Greece
Cooper Cancer Institute
🇺🇸Voorhees, New Jersey, United States
Jawaharlal Nehru Cancer Hospital & Research Centre
🇮🇳Bhopal, Madhya Pradesh, India
Kursk Regional Oncology Centre
🇷🇺Kursk, Russian Federation
Moscow Research Oncology Institute n.a. P.A.Gertsen
🇷🇺Moscow, Russian Federation
Tata Memorial Hospital
🇮🇳Mumbai, India
Linn Medical Center, Clalit Health Services
🇮🇱Haifa, Israel
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelöintézet
🇭🇺Szolnok, Hungary
Rabin Medical Center
🇮🇱Petach Tikva, Israel
Kaplan Medical Center
🇮🇱Rehovot, Israel
Academisch Ziekenhuis Maastricht
🇳🇱Maastricht, Netherlands
KK Women's and Children's Hospital
🇸🇬Singapore, Singapore
Municipal Institution of Cherkasy Regional Counsil "Cherkasy Regional Oncology Dispensary"
🇺🇦Cherkasy, Ukraine
Russian Oncology Research Center named after N.N. Blokhin
🇷🇺Moscow, Russian Federation
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii
🇵🇱Olsztyn, Poland
Hospital de São João
🇵🇹Porto, Portugal
The Chaim Sheba Medical Center
🇮🇱Ramat-Gan, Israel
Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Pozna
🇵🇱Poznan, Poland
Medical Radiology Research Center of RAMS
🇷🇺Obninsk, Russian Federation
Chernivtsi Regional Clinical Oncology Dispansery
🇺🇦Chernivtsi, Ukraine
University Of Alabama At Birmingham
🇺🇸Birmingham, Alabama, United States
Humanitas Centro Catanese di Oncologia
🇮🇹Catania, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST
🇮🇹Meldola, Italy
Azienda Ospedaliero-Universitaria di Udine
🇮🇹Udine, Italy
Oregon Health & Science University
🇺🇸Portland, Oregon, United States
Kaiser Permanente Northwest
🇺🇸Portland, Oregon, United States
Providence St. Joseph Medical Center
🇺🇸Burbank, California, United States
Arizona Oncology Associates
🇺🇸Tucson, Arizona, United States
University of California San Diego
🇺🇸La Jolla, California, United States
California Cancer Care, Inc.
🇺🇸Greenbrae, California, United States
Jupiter Medical center Physician's Group
🇺🇸Jupiter, Florida, United States
Catholic Health Initiatives
🇺🇸Cincinnati, Ohio, United States
Denver Health and Hospital Authority
🇺🇸Denver, Colorado, United States
Hematology/Oncology Associates
🇺🇸Lake Worth, Florida, United States
Oncology-Hematology Associates of W. Broward P.A.
🇺🇸Tamarac, Florida, United States
Palm Beach Cancer Institute
🇺🇸West Palm Beach, Florida, United States
Central DuPage Hospital
🇺🇸Winfield, Illinois, United States
Hematology & Oncology Specialists
🇺🇸Metairie, Louisiana, United States
Greater Baltimore Medical Center
🇺🇸Baltimore, Maryland, United States
Saint Mary's Health Care
🇺🇸Grand Rapids, Michigan, United States
Frederick Memorial Hospital
🇺🇸Frederick, Maryland, United States
Barbara Ann Kamanos Cancer Center
🇺🇸Detroit, Michigan, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
Hematology-Oncolgy Associates of NNJ-PA
🇺🇸Denville, New Jersey, United States
University of New Mexico Cancer Center
🇺🇸Albuquerque, New Mexico, United States
John Theurer Cancer Center at Hackensack University MC
🇺🇸Hackensack, New Jersey, United States
Good Samaritan Hospital Cancer Center
🇺🇸Kearney, Nebraska, United States
The Center for Cancer and Hematologic Disease
🇺🇸Camden, New Jersey, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
Carolinas Medical Center
🇺🇸Charlotte, North Carolina, United States
Presbyterian Hospital
🇺🇸Charlotte, North Carolina, United States
Willamette Valley Cancer Center
🇺🇸Springfield, Oregon, United States
Providence Oncology & Hematology Care
🇺🇸Portland, Oregon, United States
Cancer Care Associates
🇺🇸Tulsa, Oklahoma, United States
Texas Oncology, PA
🇺🇸Dallas, Texas, United States
Peninsula Cancer Institute - Riverside Gynecology Oncology
🇺🇸Newport News, Virginia, United States
St. Luke's Hospital
🇺🇸Bethlehem, Pennsylvania, United States
Gettysburg Cancer Center
🇺🇸Gettysburg, Pennsylvania, United States
Western Pennsylvania Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Northern Utah Associates
🇺🇸Ogden, Utah, United States
South Texas Oncology and Hematology, PA
🇺🇸San Antonio, Texas, United States
Scott and White Memorial Hospital
🇺🇸Temple, Texas, United States
International Beneficence Clinical Research, L.L.C.
🇺🇸Harlingen, Texas, United States
US Oncology Research
🇺🇸Wichita Falls, Texas, United States
Northern Virginia Pelvic Surgery Associates
🇺🇸Annandale, Virginia, United States
Hospital Bocalandro
🇦🇷Loma Hermosa, Argentina
Consultorios Medicos Privados SA
🇦🇷Buenos Aries, Argentina
Instituto Medico Platense
🇦🇷La Plata, Argentina
Providence Everett Medical Center
🇺🇸Everett, Washington, United States
Cancer Care Northwest-South
🇺🇸Spokane, Washington, United States
Aurora Health Care
🇺🇸West Allis, Wisconsin, United States
Fundación Sanatorio Güemes
🇦🇷Caba, Argentina
Clinica Universitaria Reina Fabiola
🇦🇷Códoba, Argentina
Centro Oncologico Riojano Integral (CORI)
🇦🇷La Rioja, Argentina
Centro Médico San Roque
🇦🇷San Miguel de Tucuman, Argentina
UZ Leuven
🇧🇪Leuven, Belgium
Tweed Hospital
🇦🇺Tweed Heads, New South Wales, Australia
North Adelaide Oncology Clinical Trials
🇦🇺North Adelaide, South Australia, Australia
Centro Medico de Alta Complejidad Cemac
🇦🇷San Salvador de Jujuy, Argentina
Landeskrankenhaus Villach
🇦🇹Villach, Austria
ISIS Centro Especializado de LUCE SA
🇦🇷Santa Fe, Argentina
Kaiser-Franz-Josef Spital
🇦🇹Wien, Austria
Krankenhaus Wien-Hietzing
🇦🇹Wien, Austria
Institut Jules Bordet
🇧🇪Bruxelles, Belgium
Sir Charles Gairdner Hospital
🇦🇺Nedlands, Western Australia, Australia
AZ Groeninge - Campus Maria's Voorzienigheid
🇧🇪Kortrijk, Belgium
Associação Hospital de Caridade Ijuí
🇧🇷Ijuí, Brazil
Clinica de Neoplasias Litoral
🇧🇷Itajai, Brazil
Instituto Ribeirãopretano de Combate ao Câncer
🇧🇷Ribeirão Preto, Brazil
UZ Gent
🇧🇪Gent, Belgium
CHU de Liège
🇧🇪Liège, Belgium
Instituto de Pesquisas Clínicas para Estudos Multicêntricos
🇧🇷Caxias do Sul, Brazil
Liga Norte-Riograndense Contra o Câncer
🇧🇷Natal, Brazil
Sint-Augustinuskliniek
🇧🇪Wilrijk, Belgium
Fundação Pio XII - Hospital de Câncer de Barretos
🇧🇷Barretos, Brazil
Clínica AMO - Assistência Multidiciplinar em Oncologia
🇧🇷Salvador, Brazil
Saúde ABC Serviços Médicos Hospitalares Ltda
🇧🇷Santo André, Brazil
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
Cancer Center For The Southern Interior
🇨🇦Kelowna, British Columbia, Canada
Hospital Premier
🇧🇷São Paulo, Brazil
British Columbia Cancer Agency
🇨🇦Surrey, British Columbia, Canada
BCCA
🇨🇦Vancouver, British Columbia, Canada
Krankenhaus Nordwest
🇩🇪Frankfurt, Germany
Ottawa Hospital
🇨🇦Ottawa, Ontario, Canada
Ninewells Hospital
🇬🇧Dundee, United Kingdom
Universitätsklinikum Essen
🇩🇪Essen, Germany
Instituto Oncologico Ltda.
🇨🇱Viña del Mar, Chile
Institut Paoli Calmettes
🇫🇷Marseille, France
Hôpital Saint Louis
🇫🇷Paris Cedex 10, France
Frauenarztpraxis Dr. med. Gröll de Rivera
🇩🇪Ebersberg, Germany
Bács-Kiskun Megyei Önkormányzat Kórháza
🇭🇺Kecskemét, Hungary
Papageorgiou General Hospital
🇬🇷Thessaloniki, Greece
Queen Mary Hospital
🇭🇰Pokfulam, Islands, Hong Kong
Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
Regional Cancer Centre
🇮🇳Trivandrum, India
Albert Schweitzer Ziekenhuis
🇳🇱Dordrecht, Netherlands
Orbis Medisch Centrum
🇳🇱Sittard-Geleen, Netherlands
Cebu Gynecologic Cancer Care Clinic
🇵🇭Cebu, Philippines
Ospedale Mater Salutis ULSS 21 della regione Veneto
🇮🇹Legnago, Italy
Fondazione Centro San Raffaele del Monte Tabor
🇮🇹Milano, Italy
Union Medica Quirurgica de Colima
🇲🇽Colima, Mexico
Presidio Ospedaliero Vito Fazzi
🇮🇹Lecce, Italy
Azienda Ospedaliera Niguarda Cà Granda
🇮🇹Milano, Italy
Cheil General Hospital & Women's Healthcare Center
🇰🇷Seoul, Korea, Republic of
Seoul national univercity hospital
🇰🇷Seoul, Korea, Republic of
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
🇮🇹Milano, Italy
VU Medisch Centrum
🇳🇱Amsterdam, Netherlands
Manila Doctors Hospital
🇵🇭Manila, Philippines
Ospedale Santa Maria della Misericordia di Perugia
🇮🇹Perugia, Italy
Istituto Nazionale per lo studio e la cura dei tumori "Fondazione Giovanni Pascale"
🇮🇹Napoli, Italy
Ospedale Sacro Cuore Don Calabria
🇮🇹Negrar, Italy
Istituto Oncologico Veneto
🇮🇹Padova, Italy
Arcispedale Santa Maria Nuova
🇮🇹Reggio Emilia, Italy
Perpetual Succour Hospital
🇵🇭Cebu City, Cebu, Philippines
San Juan de Dios Hospital
🇵🇭Pasay City, Philippines
Wojewodzkie Centrum Onkologii
🇵🇱Gdansk, Poland
Centrum Onkologii, Instytut im. M. Sklodowskiej-Curie oddzial w Gliwicach
🇵🇱Gliwice, Poland
Centrum Onkologii Ziemi Lubelskiej
🇵🇱Lublin, Poland
Olsztynski Osrodek Onkologiczny "Kopernik" Sp. z o.o.
🇵🇱Olsztyn, Poland
Wielkopolskie Centrum Onkologii
🇵🇱Poznan, Poland
Azienda Policlinico Umberto I
🇮🇹Roma, Italy
Policlinico Universitario "A. Gemelli"
🇮🇹Roma, Italy
Ospedale Santa Maria delle Croci
🇮🇹Ravenna, Italy
St. Luke's Medical Center
🇵🇭Quezon City, Philippines
National Kidney and Transplant Institute
🇵🇭Quezon City, Philippines
Bialostockie Centrum Onkologii
🇵🇱Bialystok, Poland
Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
🇵🇱Lodz, Poland
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Volyn Regional Oncology Dispensary
🇺🇦Lutsk, Ukraine
SPZOZ Wojewodzki Szpital Specjalistyczny nr 3
🇵🇱Rybnik, Poland
Samodzielny Publiczny Szpital Kliniczny nr 2 PAM w Szczecinie
🇵🇱Szczecin, Poland
Hospitais da Universidade de Coimbra
🇵🇹Coimbra, Portugal
Republican Clinical Oncology Center of Bashkortostan Republic Ministry of Healthcare
🇷🇺Ufa, Russian Federation
National University Hospital
🇸🇬Singapore, Singapore
National Cancer Centre
🇸🇬Singapore, Singapore
Hospital Mutua de Terrassa
🇪🇸Terrassa, Cataluña, Spain
Wojskowy Instytut Medyczny
🇵🇱Warszawa, Poland
Russian Oncology Research Center
🇷🇺Moscow, Russian Federation
Instituto Portugues de Oncologia de Lisboa Francisco Gentil (IPOLFG, EPE)
🇵🇹Lisboa, Portugal
Instituto Português de Oncologia Francisco Gentil, Centro Regional de Oncologia de Coimbra, EPE
🇵🇹Coimbra, Portugal
Chang Gung Memorial Hospital
🇨🇳Taoyuan, Taiwan
Beatson Oncology Centre
🇬🇧Glasgow, United Kingdom
Leicester Royal Infirmary
🇬🇧Leicester, United Kingdom
Santa Casa da Misericórdia de Curitiba
🇧🇷Curitiba, Brazil
Instituto do Câncer do Ceará - ICC
🇧🇷Fortaleza, Brazil
Irmandade Santa Casa de Misericórdia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hosp. Araujo Jorge
🇧🇷Goiania, Brazil
Hospital Amaral Carvalho
🇧🇷Jaú, Brazil
Clínica de Oncologia de Porto Alegre S/S Ltda
🇧🇷Porto Alegre, Brazil
Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
🇧🇷Salvador, Brazil
Centro de Estudos de Oncologia da FMABC
🇧🇷Santo André, Brazil
National Cancer Center
🇰🇷Gyeonggi-do, Korea, Republic of
Severance Hospital, Yonsei University College of Medicine
🇰🇷Seoul, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷In Cheon, Korea, Republic of
Klinikum Traunstein
🇩🇪Traunstein, Germany
Rotkreuzklinikum München
🇩🇪München, Germany
University of Colorado
🇺🇸Aurora, Colorado, United States
Center for Cancer and Blood Disorders
🇺🇸Bethesda, Maryland, United States
Hospital Virgen del Rocio
🇪🇸Sevilla, Andalucía, Spain
Hospital Universitario Reina Sofia
🇪🇸Córdoba, Andalucía, Spain
Hospital de Mataró
🇪🇸Mataró, Cataluña, Spain
Hospital Clinic i Provincial
🇪🇸Barcelona, Cataluña, Spain
Corporació Sanitaria Parc Taulí
🇪🇸Sabadell, Cataluña, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Madrid, Communidad De, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Madrid, Communidad De, Spain
Hospital 12 de Octubre
🇪🇸Madrid, Madrid, Communidad De, Spain
Stanford University
🇺🇸Stanford, California, United States
Sarasota Memorial Healthcare System
🇺🇸Sarasota, Florida, United States
Medical College of Georgia
🇺🇸Augusta, Georgia, United States
Gulfcoast Oncology
🇺🇸Saint Petersburg, Florida, United States
Ingalls Memorial Hospital
🇺🇸Harvey, Illinois, United States
Memorial Health University Medical Center
🇺🇸Savannah, Georgia, United States
St. Francis Hospital & Health Centers
🇺🇸Indianapolis, Indiana, United States
MetroHealth Medical Center
🇺🇸Cleveland, Ohio, United States
Harrison Bremerton Hematology and Oncology
🇺🇸Bremerton, Washington, United States
Signal Point Clinical Research Center, LLC
🇺🇸Middletown, Ohio, United States
Westmead Hospital
🇦🇺Westmead, New South Wales, Australia
University of California Davis Cancer Center
🇺🇸Sacramento, California, United States
Piedmont Hematology & Oncology
🇺🇸Winston-Salem, North Carolina, United States
St. Vincent Gynecologic Oncology
🇺🇸Indianapolis, Indiana, United States
Certo Oncologia
🇧🇷São Paulo, Brazil
Instituto do Câncer Arnaldo Vieira de Carvalho
🇧🇷São Paulo, Brazil
Arizona Hematology & Oncology Associates
🇺🇸Phoenix, Arizona, United States
Oncology Specialties, PC
🇺🇸Huntsville, Alabama, United States
Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
University of California Los Angeles Medical Center
🇺🇸Los Angeles, California, United States
Palm Beach Institute of Hematology and Oncology
🇺🇸Boynton Beach, Florida, United States
Washington Hospital Center
🇺🇸Washington, District of Columbia, United States
University Cancer Institute
🇺🇸Boynton Beach, Florida, United States
Lakeland Regional Cancer Center
🇺🇸Lakeland, Florida, United States
Medical & Surgical Specialists, LLC
🇺🇸Galesburg, Illinois, United States
Midwest Cancer Research Group
🇺🇸Skokie, Illinois, United States
Park Nicollet Institute
🇺🇸Saint Louis Park, Minnesota, United States
Saint Francis Memorial Health Center
🇺🇸Grand Island, Nebraska, United States
Arena Oncology Associates
🇺🇸Lake Success, New York, United States
Roswell Park Cancer Institute
🇺🇸Buffalo, New York, United States
Columbia University Medical Center
🇺🇸New York, New York, United States
Miami Valley Hospital
🇺🇸Dayton, Ohio, United States
Oncology Hematology Associates
🇺🇸DuBois, Pennsylvania, United States
Chattanooga's Program in Women's Oncology
🇺🇸Chattanooga, Tennessee, United States
Abington Memorial Hospital
🇺🇸Abington, Pennsylvania, United States
Texas Oncology, P.A.
🇺🇸Bedford, Texas, United States
Hospital Zonal Especializado en Oncología de Lanús
🇦🇷Buenos Aires, Argentina
Centro Oncologico Integral
🇦🇷Mar Del Plata, Argentina
Mater Adult Hospital
🇦🇺South Brisbane, Queensland, Australia
The Royal Brisbane and Women's Hospital
🇦🇺Herston, Queensland, Australia
Cliniques Universitaires Saint-Luc
🇧🇪Bruxelles, Belgium
Clínica Oncologistas Associados
🇧🇷Rio de Janeiro, Brazil
INCA - Instituto Nacional do Câncer
🇧🇷Rio De Janeiro - RJ, Brazil
Instituto de Terapias Oncologicas
🇨🇱Santiago, Chile
Instituto Clínico Oncológico del Sur
🇨🇱Temuco, Chile
Centre Régional de lutte contre le cancer Paul Papin
🇫🇷Angers Cedex 9, France
Centre Hospitalier Louis Pasteur
🇫🇷Le Coudray, France
Klinikum Chemnitz gGmbH
🇩🇪Chemnitz, Germany
Institut Jean Godinot - Centre de lutte contre le cancer
🇫🇷Reims, France
Charité - Universitätsmedizin Berlin
🇩🇪Berlin, Germany
Helios Klinikum Berlin-Buch
🇩🇪Berlin-Buch, Germany
Marien-Hospital Akademisches Lehrkrankenhaus
🇩🇪Düsseldorf, Germany
Universitätsklinikum Freiburg
🇩🇪Freiburg, Germany
Kath. Marienkrankenhaus gGmbH
🇩🇪Hamburg, Germany
Universität Heidelberg
🇩🇪Heidelberg, Germany
Klinikum der Universität München - Innenstadt
🇩🇪München, Germany
Universitätsklinik Magdeburg
🇩🇪Magdeburg, Germany
St. Vincentius Kliniken Karlsruhe
🇩🇪Karlsruhe, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
🇩🇪Mainz, Germany
Klinikum Südstadt Rostock
🇩🇪Rostock, Germany
University General Hospital of Patras
🇬🇷Patras, Greece
University General Hospital of Heraklion
🇬🇷Heraklion, Crete, Greece
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Tuen Mun Hospital
🇭🇰Tuen Mun, Hong Kong
Petz Aladár Megyei Oktató Kórház
🇭🇺Gyor, Hungary
Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház
🇭🇺Miskolc, Hungary
Apollo Hospitals International Limited
🇮🇳Gandhinagar, Gujarat, India
Kidwai Memorial Institute of Oncology
🇮🇳Bangalore, Karnataka, India
Jehangir, Clinical Development Centre
🇮🇳Pune, Maharashtra, India
MNJ Institute of Oncology and Regional Cancer Centre
🇮🇳Hyderabaad, India
Dr. Kamakshi Memorial Hospital
🇮🇳Chennai, Tamil Nadu, India
Chittaranjan National Cancer Institute
🇮🇳Kolkata, West Bengal, India
M.S Ramaiah Medical College and Teaching Hospital Ethical Review Board
🇮🇳Bangalore, India
Amrita Institute of Medical Sciences and Research Centre
🇮🇳Cochin, India
Bhagwan Mahaveer Cancer Hospital and Research Centre
🇮🇳Jaipur, India
SK Soni Hospital
🇮🇳Jaipur, India
Lakeshore Hospital
🇮🇳Kochi, India
Curie Manavata Cancer Centre
🇮🇳Nasik, India
Shatabdi Superspeciality Hospital
🇮🇳Nashik, India
Rambam Medical Center
🇮🇱Haifa, Israel
Wolfson Centre
🇮🇱Holon, Israel
All India Institute of Medical Sciences
🇮🇳New Delhi, India
Hadassah University Hospital Ein Kerem
🇮🇱Jerusalem, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Assaf Harofe Medical Center
🇮🇱Zerifin, Israel
Centro di Riferimento Oncologico
🇮🇹Aviano, Pordenone, Italy
Azienda Ospedaliera Santi Antonio, Biagio e Cesare Arrigo
🇮🇹Alessandria, Italy
Centro di Ricerca e Formazione ad Alta Tecnologia nelle Scienze Biomediche
🇮🇹Campobasso, Italy
Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
🇮🇹Bologna, Italy
Istituto Ospedaliero Fondazione Poliambulanza
🇮🇹Brescia, Italy
Azienda Ospedaliera Cannizzaro
🇮🇹Catania, Italy
Azienda Ospedaliera Sant'Anna
🇮🇹Como, Italy
Ospedale di Faenza
🇮🇹Faenza, Italy
Azienda Ospedaliera Universitaria San Martino
🇮🇹Genova, Italy
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Triva Investigaciones Medicas Sociedad Anónima de Capital Variable
🇲🇽Morelia, Mexico
Hospital Regional de Veracruz
🇲🇽Veracruz, Mexico
Instituto Portugues de Oncologia do Porto Francisco Gentil (IPOPFG, EPE)
🇵🇹Porto, Portugal
City Clinical Oncology Dispensary
🇷🇺St. Petersburg, Russian Federation
Ryazan Regional Clinical Oncology Dispensary
🇷🇺Ryazan, Russian Federation
Hospital Son Llatzer
🇪🇸Palma de Mallorca, Baleares, Spain
Hospital Universitario Vall D'Hebron
🇪🇸Barcelona, Cataluna, Spain
Fundación Instituto Valenciano de Oncología
🇪🇸Valencia, Comunidad Valenciana, Spain
Hospital General Universitario de Elche
🇪🇸Elche, Comunidad Valenciana, Spain
Fundacion Hospital Alcorcon
🇪🇸Alcorcón, Madrid, Communidad De, Spain
National Cheng Kung University Hosptial
🇨🇳Tainan, Taiwan
Universität Zürich
🇨🇭Zürich, Switzerland
Mackay Memorial Hospital
🇨🇳Taipei, Taiwan
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Kiev City Oncology Hospital
🇺🇦Kyiv, Ukraine
Velindre Hospital
🇬🇧Cardiff, United Kingdom
University Hospital Coventry
🇬🇧Coventry, United Kingdom
Belfast City Hospital
🇬🇧Belfast, United Kingdom
Royal Marsden Hospital
🇬🇧London, United Kingdom
Hammersmith Hospital
🇬🇧London, United Kingdom
Derriford Hospital
🇬🇧Plymouth, United Kingdom
Poole Hospital NHS Trust
🇬🇧Poole, United Kingdom
Clatterbridge Centre For Oncology
🇬🇧Wirral, United Kingdom
Weston Park Hospital
🇬🇧Sheffield, United Kingdom
New Cross Hospital
🇬🇧Wolverhampton, United Kingdom
Gainsville Hematology Oncology Associates
🇺🇸Gainesville, Florida, United States
Florida Hospital
🇺🇸Orlando, Florida, United States
Kaiser Permanente - Moanalua Medical Center
🇺🇸Honolulu, Hawaii, United States
Kapi'olani Medical Center for Women and Children
🇺🇸Honolulu, Hawaii, United States
Central Baptist Hospital
🇺🇸Lexington, Kentucky, United States
University of Louisville
🇺🇸Louisville, Kentucky, United States
Norton Healthcare
🇺🇸Louisville, Kentucky, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Baptist Cancer Institute
🇺🇸Jacksonville, Florida, United States
Northwest Cancer Specialists, PC
🇺🇸Vancouver, Washington, United States
Ruby Hall Clinic
🇮🇳Pune, Maharashtra, India